Widely used:Recently Viewed
Clear All
$56 Mln
--
238.54
108.72
-3.21
--
--
--
--
-1876749
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Verrica Pharmaceuticals (VRCA)
| -81.69 | -29.84 | -82.44 | -66.50 | -52.03 | -37.87 | -- |
|
BSE Sensex
| 12.20 | -0.16 | 1.32 | 22.81 | 11.05 | 16.56 | 11.80 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2023
|
2022
|
2021
|
2020
|
2019
|
|
|---|---|---|---|---|---|
|
Verrica Pharmaceuticals (VRCA)
| 166.18 | -69.98 | -20.42 | -27.56 | 94.97 |
|
S&P Small-Cap 600
| 13.89 | -17.42 | 25.27 | 9.57 | 20.86 |
|
BSE Sensex
| 18.74 | 4.44 | 21.99 | 15.75 | 14.38 |
|
Stock
|
Peer Median
|
||
|---|---|---|---|
loading... |
|||
|
Stock
|
Peer Median
|
||
|---|---|---|---|
loading... |
|||
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Our rating system has guided millions of investors in the past 20 years.
$55.90 Mln
$13.91 Mln
$0.00 Mln
$31.93 Mln
$46.31 Mln
High
$1.04 - 11.40
42,668,600
NASDAQ: VRCA
West Chester, PA
https://www.verrica.com
Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for... the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania. Read more
The total asset value of Verrica Pharmaceuticals Inc (VRCA) stood at $ 72 Mln as on 30-Jun-24
The share price of Verrica Pharmaceuticals Inc (VRCA) is $1.34 (NASDAQ) as of 07-Oct-2024 16:05 EDT. Verrica Pharmaceuticals Inc (VRCA) has given a return of -52.03% in the last 3 years.
Verrica Pharmaceuticals Inc (VRCA) has a market capitalisation of $ 56 Mln as on 04-Oct-2024. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Verrica Pharmaceuticals Inc (VRCA) is 238.54 times as on 04-Oct-2024, a 5108% premium to its peers’ median range of 4.58 times.
Since, TTM earnings of Verrica Pharmaceuticals Inc (VRCA) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Verrica Pharmaceuticals Inc (VRCA) and enter the required number of quantities and click on buy to purchase the shares of Verrica Pharmaceuticals Inc (VRCA).
Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
The CEO & director of Mr. Ted White. is Verrica Pharmaceuticals Inc (VRCA), and CFO & Sr. VP is Mr. Ted White.
There is no promoter pledging in Verrica Pharmaceuticals Inc (VRCA).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,093
|
|
|
841
|
|
|
717
|
|
|
673
|
| Verrica Pharmaceuticals Inc. (VRCA) | Ratios |
|---|---|
|
Return on equity(%)
|
--
|
|
Operating margin(%)
|
-564.65
|
|
Net Margin(%)
|
-625.06
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Verrica Pharmaceuticals Inc (VRCA) was $0 Mln.
$0.03
